Calculate exact reconstitution volumes, insulin units, and doses per vial for any peptide.
Hexarelin (also known as examorelin) is a synthetic hexapeptide belonging to the class of growth hormone releasing peptides (GHRPs). It is composed of six amino acids and is structurally derived from GHRP-6, but with a targeted modification of one tryptophan residue to D-2-methyl-tryptophan. This change gives Hexarelin greater metabolic stability and makes it one of the most potent members of the first generation of GHRPs. Hexarelin is supplied as a lyophilized powder and, for research purposes, is reconstituted with bacteriostatic water and administered subcutaneously or intramuscularly.
Hexarelin was studied intensively during the late 1980s and 1990s, originally as a candidate for the treatment of growth hormone deficiency. That period generated an unusually broad body of preclinical and early clinical evidence, which sets Hexarelin apart from many other research peptides. Alongside its strong release of growth hormone (GH), one striking finding was a distinct, GH-independent effect on the cardiovascular system that remains an active area of research today. This cardiac component clearly differentiates Hexarelin from more selective GHRPs such as ipamorelin.
Compared with other secretagogues, Hexarelin is considered exceptionally potent: each administration triggers a strong GH pulse. That strength has a trade-off, however, because research shows that Hexarelin is prone to pronounced desensitization of the pituitary system with continuous use. For this reason, research protocols typically use Hexarelin only in short, time-limited phases rather than treating it as a continuous-use peptide. Hexarelin is neither an approved drug nor an anabolic steroid; it works indirectly through the body's own GH axis.
Hexarelin exerts its effects primarily by activating the ghrelin receptor, which triggers a cascade of hormonal and tissue-specific responses:
In research, Hexarelin is used in comparatively small amounts per administration and is typically dosed several times per day to mimic the body's natural pulsatile GH release. Because of its marked tendency toward desensitization, higher doses are not automatically better, and a conservative approach is sensible.
Hexarelin is commonly available in 2 mg and 5 mg vials. Reconstituting a 5 mg vial with 2 mL of bacteriostatic water produces a concentration of 2.5 mg/mL (2,500 mcg/mL).
At a standard dose of 100 mcg administered three times daily, 300 mcg is used per day. A 5 mg vial therefore lasts roughly 16–17 days. Because Hexarelin is dosed in small volumes, a precise syringe with fine graduations is important. Use the Hexarelin calculator above to determine exact volumes for any vial size, reconstitution volume, and target dose.
Hexarelin is supplied as a lyophilized (freeze-dried) powder in sealed vials and must be reconstituted with bacteriostatic water (BAC water) before use in research settings. BAC water contains 0.9% benzyl alcohol, which inhibits microbial growth and extends the usable window of the reconstituted solution. Sterile water for injection is not suitable for multi-dose vials.
If the solution appears cloudy, discolored, or contains visible particulate matter, discard the vial and do not use it.
Hexarelin was studied in several early clinical trials during the 1990s and was generally well tolerated in those short-term settings. Nonetheless, large-scale long-term human data is lacking, so all use remains in the research domain. The side effects arise mainly from its mechanism as a ghrelin receptor agonist.
No serious adverse events have been reported in the short term at the research doses described in the literature. Given the absence of long-term human data, caution is warranted, and consultation with a qualified healthcare professional is strongly recommended.
The most common research approach combines a GHRP such as Hexarelin with a GHRH analog, for example CJC-1295 without DAC. The two compound classes act through different receptors and complement each other: the GHRP increases the amplitude of the GH pulse, while the GHRH analog primes the pituitary for release. In preclinical studies, this combination produces a stronger GH pulse than either compound alone. Both peptides are reconstituted separately and dosed immediately before administration.
Within the GHRP class, Hexarelin is positioned as the most potent but least selective peptide. Ipamorelin is regarded as the most selective GHRP, with minimal influence on cortisol, prolactin, and appetite, and is therefore often preferred for longer research phases. GHRP-2 and GHRP-6 sit in between, with GHRP-6 showing the strongest appetite effect. In research, Hexarelin is typically used when a particularly strong GH pulse is the focus and the protocol is planned to be time-limited anyway.
Because of its pronounced desensitization, Hexarelin is rarely run as a continuous-use peptide in research protocols. Short cycles of a few weeks, followed by a break or a switch to a more selective GHRP such as ipamorelin, are common. This rotation is intended to preserve pituitary sensitivity. Related secretagogues such as Sermorelin are also used in research within rotation and comparison protocols.
Both are GHRPs and activate the same ghrelin receptor, but they differ in potency and selectivity. Hexarelin produces a stronger GH pulse but can, at higher doses, slightly raise cortisol and prolactin and tends to desensitize quickly. Ipamorelin is weaker but highly selective and better suited to longer research phases. The choice depends on whether a short, strong pulse or a more stable, sustained application is the priority.
Hexarelin shows pronounced tachyphylaxis: with continuous use, the pituitary responds progressively more weakly to the peptide, and the GH pulse becomes smaller over time. Short cycles with clear breaks, or a switch to a more selective GHRP, are intended to preserve receptor sensitivity and counteract this fading response.
In research, Hexarelin is usually dosed with some separation from meals, since dietary fats and larger amounts of carbohydrates can blunt the GH pulse. A gap of roughly one hour before or after eating is common practice. A dose before bed is frequently scheduled on an empty stomach.
In addition to the ghrelin receptor, Hexarelin binds to the CD36 receptor in heart tissue. This pathway is independent of GH release and has been studied in preclinical models in relation to cardiac function. It is an active research field whose long-term significance is not yet fully established.
Yes, to a moderate degree. Because Hexarelin acts on the ghrelin receptor, it can increase hunger. The effect is clearly weaker than with GHRP-6 but stronger than with ipamorelin, which shows almost no appetite effect.
Because of its rapid desensitization, research protocols generally use short cycles of a few weeks, followed by a break. Longer uninterrupted phases are atypical, because the GH response then noticeably declines. The exact duration depends on the study design.
Yes. Combining a GHRP with a GHRH analog is the most common research approach, since the two act through different receptors and complement each other. The two peptides are reconstituted separately and dosed immediately before administration to avoid stability concerns.
Yes. Growth hormone secretagogues and GHRPs are listed on the WADA prohibited list as banned substances and are prohibited at all times. Athletes subject to anti-doping testing should treat Hexarelin as a prohibited substance and verify the rules applicable to their sport before any use.
Medical Disclaimer: The information on this page is provided for educational and research purposes only. Hexarelin is not an approved drug or medical treatment and is supplied strictly for research use. Nothing on this page constitutes medical advice, diagnosis, or a recommendation to use any specific compound. Always consult a qualified healthcare professional before beginning any peptide protocol. BergdorfBio assumes no liability for the use or misuse of the information presented here.